Amgen Inc. $AMGN Shares Sold by WealthPLAN Partners LLC

Posted by Brenda Bartman on Jul 8th, 2026

WealthPLAN Partners LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 27.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,780 shares of the medical research company’s stock after selling 2,614 shares during the quarter. WealthPLAN Partners LLC’s holdings in Amgen were worth $2,386,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of AMGN. Vanguard Group Inc. raised its holdings in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares during the period. State Street Corp increased its position in shares of Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after acquiring an additional 1,287,310 shares in the last quarter. Capital World Investors increased its position in shares of Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares in the last quarter. Capital International Investors raised its holdings in shares of Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after acquiring an additional 282,219 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen received an upgrade to Zacks Rank #2 (Buy), which signals improving earnings expectations and could help sentiment near term.
Positive Sentiment: Biotech stocks may be getting a boost from a more favorable M&A backdrop, with Jim Cramer calling biotech “the hottest group in the market” and suggesting deal activity could accelerate.
Positive Sentiment: Several analysts raised or reaffirmed price targets on AMGN, including Truist lifting its target to $340 and Cantor Fitzgerald reaffirming a neutral stance with a $350 target, which still reflects solid long-term value expectations.
Neutral Sentiment: Commentary on Amgen’s dividend safety suggests investors are still weighing near-term headwinds against the company’s cash generation and payout profile.
Negative Sentiment: Amgen initiated broad U.S. recalls of Sensipar and Corlanor tied to CGMP deviations and contamination concerns, raising quality-control questions across multiple lots and dosage strengths.
Negative Sentiment: Ongoing scrutiny around Tavneos and pipeline uncertainty continue to weigh on the shares, as regulators challenge the drug’s approval and investors reassess future growth prospects.

Analyst Upgrades and Downgrades

AMGN has been the topic of several recent analyst reports. BMO Capital Markets reissued an “outperform” rating and set a $400.00 price target on shares of Amgen in a research report on Wednesday, July 1st. Mizuho raised their price objective on Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 16th. Guggenheim lowered their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research note on Monday, May 4th. Argus dropped their target price on Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday, May 20th. Finally, The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a report on Friday, June 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $356.00.

Get Our Latest Stock Report on Amgen

Amgen Stock Performance

Shares of AMGN opened at $368.10 on Wednesday. The company has a market capitalization of $198.67 billion, a PE ratio of 25.62, a price-to-earnings-growth ratio of 3.61 and a beta of 0.41. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a one year low of $269.77 and a one year high of $391.29. The company’s fifty day moving average price is $343.26 and its 200 day moving average price is $348.66.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts expect that Amgen Inc. will post 22.39 earnings per share for the current year.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.85% of the company’s stock.

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.